Abstract: Quercetin and/or naringenin in combination with either retinol or retinyl ester resulted in a synergistic inhibition of keratinocyte differentiation. The effects of the retinol or retinyl esters in combination with naringenin and/or quercetin were analogous to treatment with retinoic acid.

Abstract: Compositions which contain, as the active ingredients, a combination of heterocyclic compounds of the general formula (I) and organophosphorous compounds, in addition to an amorphous silica additive selected from the class consisting of:(a) an amorphous silica obtained by a process, wherein an amorphous silica hydrate, which has been produced by a wet synthetic, method, is either silylated or heated to effect an etherification so as to decrease the surface silanol radicals of the amorphous silica hydrate, and(b) an anhydrous, amorphous silica obtained by a dry synthetic method, or a silylated derivative thereof,and optionally one or more compounds having a polyethyleneglycol or polypropyleneglycol chain or an ethyleneglycolpropyleneglycol copolymeric chain, or a mixture of these compounds which results in a stabilization of the active ingredients without any adverse influences on the physical properties of the formulations.

Abstract: Novel carboximidamide derivatives represented by the following formula (A) and acid adduct salts thereof are disclosed: ##STR1## wherein all the substituents have the same meanings as defined above. N-cyano-pyridinecarboximidate compounds represented by the following formula (II) which are the intermediates for preparing of N-cyano-N'-substituted-pyridinecarboximidamide derivatives wherein the substituent B in the above described formula (A) is pyridine is also disclosed: ##STR2## wherein all the substitutents have the same meanings as defined above. The process for preparing the compounds, the pharmaceutical agents comprising the compound having vasodilating effect, and the therapeutic method of dosing the compound on patients for therapy are also disclosed.